FindTrial
Sign In

Evaluation of the role of HDS technology in the screening of sensitive drugs for esophageal cancer

Evaluation of the role of HDS technology in the screening of sensitive drugs for esophageal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068566
Enrollment
Unknown
Registered
2023-02-23
Start date
2018-12-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

observation group:Screening for sensitive drugs
control group:Conventional drug chemotherapy

Sponsors

The 901 Hospital of Joint Logistics Support Force
Lead Sponsor

Eligibility

Sex/Gender
All
Age
41 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Meet the diagnostic criteria for progressive EC ? Complete clinical data ? No indication for surgery.

Exclusion criteria

Exclusion criteria: (1) cardiovascular disease; (2) penetrating ulcer; (3) hepatic and renal insufficiency; (4) coagulation disorder; (5) severe immune system disease

Design outcomes

Primary

MeasureTime frame
Tumor Markers;Long-term survival rate;Local progression rate and distant metastasis rate;—

Countries

China

Contacts

Public ContactTANG JUN

The 901 Hospital of Joint Logistics Support Force

Tangjun1974@163.com+86 18909699751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026